Enhancing the bioavailability of resveratrol by nanoencapsulation
Resveratrol (3,5,4-trihydroxystilbene) is a phytoalexin present in natural food products such as grapes, wine, peanuts, and berries with GRAS (Generally Recognised as Safe) regulatory status.
In the last years, several studies have demonstrated the potential health benefits of resveratrol. Some of these benefits are antioxidizing and anti-atherosclerosis effects, chemoprotective and cardiovascular protective effects and the capacity to inhibit platelet aggregation. However, resveratrol exhibits low stability, low water solubility and it is rapidly metabolized in vivo, which contributes to a limited cell absorption upon oral administration and therefore a very low bioavailability. Therefore, the therapeutically potential of resveratrol only will be achieve if the limitations tied to its low bioavailability are overcome.
In the last years, interest in nanotechnology has grown considerably, and researchers have investigated its use in increasing the clinical efficacy of natural products, such as resveratrol. Zein nanoparticles promote a 20-fold increase of resveratrol´s bioavailability in rats. Furthermore, the efficacy of this nanoparticles was proved in a mouse model of endotoxic shock. These nanoparticles were able to diminish the endotoxic symptoms induces by the ip administration of LPS.
In the light of these reports, Nucaps, in collaboration with Idifarma, is exploring the feasibility of the oral administration in humans of resveratrol-loaded zein nanoparticles. For this purpose, zein nanoparticles are being transfer from a laboratory scale to pilot and industrial scale and the hypothesis proved in rats, that these kind of nanocarriers can increase the bioavailability of resveratrol will be tested in humans.
- Title: NANOCAPS
- Identification Number: 0011-1365-2018-000285
- Implementation period: February 2018-December 2019
- Partners: NUCAPS Nanotechnology, S.L., IDIFARMA desarrollos farmacéuticos S.L.
This project has been approved by the Government of Navarre in the R&D projects 2018 call and it is co-financed (50%) by the FEDER funds through the Programa Operativo 2014-2020 de Navarra.
This enterprise has received a 50% co-financed grant by the European Regional Development Fund through the Programa Operativo FEDER 2014-2020 de Navarra.